BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach. J Biomed Biotechnol. 2012;2012:103763. [PMID: 22500073 DOI: 10.1155/2012/103763] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 De Cock RF, Allegaert K, Sherwin CM, Nielsen EI, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014;31:754-67. [PMID: 24065592 DOI: 10.1007/s11095-013-1197-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
2 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Girardi A, Raschi E, Galletti S, Poluzzi E, Faldella G, Allegaert K, De Ponti F. Drug-induced renal damage in preterm neonates: state of the art and methods for early detection. Drug Saf 2015;38:535-51. [PMID: 25863473 DOI: 10.1007/s40264-015-0288-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.6] [Reference Citation Analysis]
4 Kulo A, van Calsteren K, Verbesselt R, Smits A, Devlieger R, de Hoon J, Allegaert K. The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. J Biomed Biotechnol. 2012;2012:437639. [PMID: 22675252 DOI: 10.1155/2012/437639] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
5 Sage DP, Kulczar C, Roth W, Liu W, Knipp GT. Persistent pharmacokinetic challenges to pediatric drug development. Front Genet 2014;5:281. [PMID: 25221567 DOI: 10.3389/fgene.2014.00281] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
6 Smits A, De Cock P, Vermeulen A, Allegaert K. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute. Expert Opin Drug Metab Toxicol 2019;15:25-34. [PMID: 30554542 DOI: 10.1080/17425255.2019.1558205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
7 Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology. International Journal of Pharmaceutics 2013;452:8-13. [DOI: 10.1016/j.ijpharm.2012.03.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
8 Duan P, Fisher JW, Wang J. Applications of Physiologically Based Pharmacokinetic (PBPK) Models for Pediatric Populations. In: Mahmood I, Burckart G, editors. Fundamentals of Pediatric Drug Dosing. Cham: Springer International Publishing; 2016. pp. 109-25. [DOI: 10.1007/978-3-319-43754-5_8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Edginton AN. Using Physiologically Based Pharmacokinetic Modeling for Mechanistic Insight: Cases of Reverse Translation. Clin Transl Sci 2018;11:109-11. [PMID: 29084377 DOI: 10.1111/cts.12517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Allegaert K, Fanos V, van den Anker JN, Laër S. Perinatal pharmacology. Biomed Res Int 2014;2014:101620. [PMID: 24822175 DOI: 10.1155/2014/101620] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]